To help alleviate the burden of visceral leishmaniasis, Gilead Sciences struck a deal with the World Health Organization to donate 445,000 vials of liposomal amphotericin B, which is used to treat the devastating disease, during the next five years, The Lancet Infectious Diseases reports.
Read more